Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Anchorage, Alaska +259 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
NCT06367972
Recruiting
To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \[the removal or destruction of a body part or tissue or its function\], or embolization \[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: OligoProgressive Metastatic Disease
Register for Updates
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044
Recruiting
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/25/2025
Locations: Levenson Eye Associates, Jacksonville, Florida +4 locations
Conditions: Thyroid Eye Disease
Register for Updates
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
NCT06409052
Recruiting
To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326
Recruiting
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy has been shown to improve overall survival compared to patients receiving surgery first. Gemcitabine is a chemot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Register for Updates
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
NCT06450353
Recruiting
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Allogeneic Transplantation
Register for Updates
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Patty & George Hoag Cancer Center, Newport Beach, California +278 locations
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates
Developing a Novel Human Laboratory Paradigm for AUD Medication Screening
NCT06489782
Recruiting
The intent of the study is to develop two versions of the 'ability to resist' drinking model designed to screen Alcohol Use Disorder (AUD) medications.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2025
Locations: Sierra Pacific Arthritis and Rheumatology Centers, Fresno, California +81 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384
Recruiting
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabiliz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: GSK Investigational Site, Los Angeles, California +119 locations
Conditions: Lung Diseases, Interstitial
Register for Updates
Drinking, Acetate, and Stress
NCT06584448
Recruiting
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results will lead us to find more effective ways to help people stop or reduce drinking when participants are drinking at harmful levels.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/25/2025
Locations: The Anlyan Center, 300 Cedar St., New Haven, Connecticut +1 locations
Conditions: Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
Register for Updates
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
NCT06605430
Recruiting
Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: HealthPartners Cancer Research Center, Saint Louis Park, Minnesota
Conditions: Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
Register for Updates